The Netherlands
Bi/ond, founded in 2017, is a Netherlands-based innovator at the intersection of Biotechnology and Semiconductor industries. Their slogan, "Accurate disease models and more personalized medicine, by recreating human physiology & pathology in a 3D model," encapsulates their mission to revolutionize drug testing and medical research.
Offering customizable Organ-on-Chips (OOCs), Bi/ond’s technology aims to surpass the limitations of traditional in vitro assays by providing accurate simulations of human physiology. Their platforms create dynamic cell culture environments, enabling precise drug testing and reducing reliance on animals, aligning with the 3Rs principle—Replacement, Reduction, and Refinement.
Despite its promising technology, Bi/ond's last investment was a seed round on 09 March 2022, though details about the investors remain undisclosed. This positions Bi/ond as a company with strong growth potential, seeking further investment to scale its innovative solutions.
